Peter Matzneller results 4
· Newest (Page 1/1, per page 25)
Author: Peter Matzneller ×Clear All Filters
Search Results
Pulmonary surfactant impacts in vitro activity of selected antifungal drugs against Candida krusei and Candida albicansNARA Subscribed
Purpose This study investigates how surfactants affect the in-vitro anti-infective efficacy of micafungin, caspofungin, anidulafungin, and amphotericin B in treating pulmonary mycoses. Methods MIC values for antifungal agents were determined against Candida krusei (now Pichia kudriavzevii ) ATCC 6258, Candida albicans ATCC 90028, and 18 clinical isolates using the broth microdilution method in RPMI medium, following EUCAST rec...
Population plasma and urine pharmacokinetics and the probability of target attainment of fosfomycin in healthy male volunteersNARA Subscribed
Purpose A population pharmacokinetic model of fosfomycin was developed in healthy volunteers after intravenous administration, and different dosing regimens were evaluated in terms of the probability of target attainment for Escherichia coli using both plasma and urinary pharmacokinetic/pharmacodynamic targets. Methods Eight healthy men received fosfomycin as both intermittent 8 g q8h and continuous infusion 1 g/h with a loadi...
Perception of clinical research among patients and healthy volunteers of clinical trialsNARA Subscribed
Purpose Clinical research relies on data from patients and volunteers, yet the target sample size is often not achieved. Here, we assessed the perception of clinical research among clinical trial participants to improve the recruitment process for future studies. Methods We conducted a single-center descriptive and exploratory study of 300 current or former participants in various phase I–III clinical trials. Questionnaires we...
Previous1Next